Home Verastem Oncology

Verastem Oncology

In operation
Post-IPO Round
Small Molecule Kinase Inhibitor Developer
Basic
Enterprise Profile

Basic Information

Verastem Oncology (NASDAQ: VSTM) is a biopharmaceutical company focused on developing drugs to improve the survival and quality of life for cancer patients. Our portfolio includes small molecule kinase inhibitors that suppress key signaling pathways, promoting cancer cell survival and tumor growth.
Verastem, Inc.
Massachusetts,United States of America
101~500 people
January 01, 2010
info@verastem.com

Enterprise Profile

Industrial Sector
New Drug Development Biological Drug Production
Technology
Biotechnology
Concept
Therapeutic Products Ovarian Cancer Lung Cancer Lymphoma
Application Scenarios
Innovative Drugs